Combination Therapy of F8IL10 and Methotrexate in Rheumatoid Arthritis Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

April 30, 2017

Study Completion Date

April 13, 2017

Conditions
Rheumatoid Arthritis
Interventions
DRUG

F8IL10

"Weekly administration of F8IL10 (from 6 to 600 μg/kg), starting from 6 μg/kg cohort 1. The cohort 10 represents the last dose-level of the study.~F8IL10 will be administered as subcutaneous (s.c.) injections. Patients will receive 4 cycles of treatment unless there is unacceptable toxicity or withdrawal of consent."

DRUG

Methotrexate

"Methotrexate will be administered at a fixed dose of 10-15 mg on Day 1, orally (p.o.), subcutaneously (s.c.) or intramuscularly (i.m.).~Patients will receive 4 cycles of treatment unless there is unacceptable toxicity or withdrawal of consent."

Trial Locations (5)

Unknown

Policlinico San Matteo, Pavia, Pavia

Pisa University Hospital, Pisa

Azienda Ospedaliera San Camillo-Forlanini Roma, Roma

Policlinico A. Gemelli, Università Cattolica del Sacro Cuore, Roma

Siena University Hospital, Siena

All Listed Sponsors
lead

Philogen S.p.A.

INDUSTRY

NCT02076659 - Combination Therapy of F8IL10 and Methotrexate in Rheumatoid Arthritis Patients | Biotech Hunter | Biotech Hunter